Sou Hu Cai Jing·2025-12-30 10:15Core Insights - The industry is experiencing intensified competition as imported GLP-1 weight loss drugs enter a price reduction phase, moving away from previously high profit margins [2][4] Group 1: Price Reductions - The imported GLP-1 weight loss drug Semaglutide (brand name: Ozempic) has seen significant price cuts, with prices dropping from 1893.67 yuan to 987.48 yuan for one specification and from 2463 yuan to 1284.36 yuan for another, effectively halving the original prices [2] - Eli Lilly's weight loss drug Tirzepatide is also undergoing price reductions in the market, with pre-sale activities initiated on e-commerce platforms [4] Group 2: Market Dynamics - The competition is heightened as Novo Nordisk's single-target GLP-1 drug Semaglutide faces direct competition from Eli Lilly's dual-target GLP-1 drug Tirzepatide and the impending market entry of biosimilars for Semaglutide [4] - Novo Nordisk's patent in the Chinese market is set to expire on March 20, 2026, with 10 domestic biosimilar applications already filed for Semaglutide [4] Group 3: Industry Impact - The price reductions of imported GLP-1 weight loss drugs indicate a breaking of the market ceiling price, suggesting that previously anticipated excess profits may no longer be achievable, although normal profit levels are expected to persist [5] - The impact of these price changes is likely to be more pronounced on the pricing strategies of upcoming GLP-1 weight loss products [5]